Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy
Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.
You may also be interested in...
Roche’s Japanese affiliate says the impact of the pandemic on its second quarter was limited, but points to a more uncertain outlook for the rest of the year, during which it vows to keep focusing on innovation.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.